More on MRK
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $131.07 |
|
|||
| Open | $131.01 | ||||
| 52 Wk High | $65.46 | ||||
| 52 Wk Low | $47.97 | ||||
| Day High | $132.53 | ||||
| Day Low | $130.45 | ||||
| P/E | 88.95 | ||||
| EPS | $1.47 | ||||
| Volume | 6,990,534 | ||||
- Merck (MRK) PT Raised to $105 at Bernstein SocGen Group
- Merck signs HIV prevention drug licenses covering 129 countries
- Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
- Tessera Therapeutics names former Merck executive as new CEO
- Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
- Gilead to present lenacapavir HIV trial data at AIDS 2026
- Gilead and Merck HIV pill shows strong results in Phase 3 trials
- Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
- Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
- Phanes expands Merck collaboration to study cancer drug combination
Entities mentioned with MRK
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
